secwatch.observer — SEC 8-K summary
======================================

Issuer:     NKGen Biotech, Inc. (—)
CIK:        0001845459
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001104659-24-025024
Event type: regulatory
Sentiment:  negative
Materiality: 0.50
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

NKGen Biotech receives Nasdaq non-compliance notice for board independence
--------------------------------------------------------------------------

- Nasdaq notice dated Feb 13, 2024 due to insufficient independent directors after Alana McNulty's resignation.
- Board has 4 directors, only 2 independent; Audit Committee has only 2 independent members (needs 3).
- Cure period: until earlier of next annual meeting or Feb 4, 2025 (or Aug 2, 2024 if meeting before Aug 2).
- Company plans to elect one or more independent directors during cure period.
- No immediate effect on listing or trading of NKGN common or NKGNW warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845459/000110465924025024/0001104659-24-025024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845459/000110465924025024/tm246575d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-025024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer